Securities code: 002898 securities abbreviation: Sailong Pharmaceutical Group Co.Ltd(002898) Announcement No.: 2022-006 Sailong Pharmaceutical Group Co.Ltd(002898)
2021 annual performance forecast
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
(I) performance forecast period
From January 1, 2021 to December 31, 2021.
(II) performance forecast
√ the estimated net profit is negative.
The current reporting period of the project is the same period of last year
Loss attributable to listed companies: 8.75 million yuan – 17.5 million yuan loss: 67.2219 million yuan net profit of shareholders
Net profit after deducting non recurring loss: 23.75 million yuan – 33.5 million yuan loss: 96.0492 million yuan profit
Loss of basic earnings per share: 0.0497 yuan / share – 0.0994 yuan / share loss: 0.3819 yuan / share
Operating income: 240 million yuan – 260 million yuan, 120.6843 million yuan
The operating income after deduction is RMB 235 million – RMB 255 million and RMB 120.5562 million
2、 Communication with accounting firms
The performance forecast of the company has not been audited by an accounting firm, which is the preliminary calculation result of the company. The company has conducted pre communication with the annual audit accounting firm on relevant matters, and there is no difference in performance between the company and the accounting firm.
3、 Explanation of performance change reasons
The company’s operating income has increased significantly, mainly because the company’s operating environment has been greatly improved since 2021 compared with the same period last year. At the same time, the company has practically promoted various business plans, and the relevant market and sales activities have been carried out steadily. The sales layout of new products such as argatroban injection, tegacyclin for injection and tranexamic acid injection has achieved certain results, and some products have won the bid for provincial centralized purchase, The market share has gradually increased.
During the reporting period, the impact of the company’s non recurring profits and losses on the net profit was about 15 million yuan, mainly the income from equity disposal and the profit and loss from changes in fair value.
4、 Risk tips
The relevant data of this performance forecast are the results of the company’s preliminary forecast. The specific conditions of this report will be disclosed in detail in the full text of the company’s 2021 annual report. Please make careful decisions and pay attention to investment risks. It is hereby announced!
Sailong Pharmaceutical Group Co.Ltd(002898) board of directors
January 29, 2022
